PDCD1 and melanoma: Therefore, we recruited melanoma patients before beginning ICI therapy (anti‐CTLA‐4, anti‐PD‐1, anti‐CTLA‐4 + anti‐PD‐1) and analyzed the immune cell composition and function of peripheral mononuclear blood cells using flow cytometry.